Biogen Idec Reports Strong Earnings Thanks to Robust Sales Of Flagship Products

With former Exelixis chief George Scangos in the house and hinting at cultural changes, the Cambridge, Mass. biotech beat estimates with strong sales of Avonex and Rituxan. Progress in testing for the deadly JC virus could soon give Tysabri sales a lift.